SEC Form 4 · accession 0001012975-19-000039
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Klaus Schafer
Director
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 5:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F1 | $2.60 | Jan 2, 2019 | A | 20,000 | A | — | Jan 2, 2029 | Common Stock, par value $0.0001 | 20,000 | 20,000 | D |
Explanation of responses
- F1The option becomes vested and exercisable in two equal installments on February 28, 2019 and August 30, 2019, in each case, generally subject to the reporting person's continued service through the applicable vesting date.